Wachovia declares $1.1 billion writedown for October

In a filing to the Securities and Exchange Commission (SEC), America’s fourth-largest bank by assets declared that, in addition to last month’s report of third-quarter market disruption-related losses totalling $1.3 billion, the firm has had to write off almost the same amount again, due to the depreciation of CDOs and MBS exposed to subprime mortgages.

The writedown meant Wachovia had just $676 million of exposures to CDOs and MBS left on its balance sheet by October 31, a massive drop from the $1.8 billion value it placed on the same structured products just a month earlier.

The October figures presage what looks likely to be another painful quarter for institutions stuck with depreciating securities they cannot find buyers for. “Wachovia now expects to record a loan loss provision in the fourth quarter of 2007 of between $500 million and $600 million,” the SEC filing read.

Wachovia joins Citi, Morgan Stanley, Merrill Lynch and several other banks that have come forward in recent weeks with writedowns much worse than those detailed in their third-quarter reports.

Regulatory investigations into the crisis are under way, with the International Organisation of Securities Commissions setting up a task force to identify lessons to be learnt from the crisis, and the SEC investigating Merrill Lynch, which yesterday confessed a further $5.7 billion exposure to subprime markets.

See also: Morgan Stanley and Merrill Lynch reveal billions more subprime damage
Dresdner hit by credit crisis, but BNP sails through
Risk USA: Rate cuts do not “bail out Wall St”
Change at top as Citi sees writedowns

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@risk.net or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact info@risk.net to find out more.

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here